Monitor for Cboe Canada approval of the appointment and any subsequent board committee assignments. No immediate stock-moving catalyst — the appointment adds CNS regulatory expertise but does not alter near-term clinical or financial milestones.
Price Chart
Executive Summary
Helus Pharma appointed Dr. Suresh Durgam, a CNS drug-development executive with FDA approval experience (CAPLYTA), to its Board of Directors. The appointment is routine for a clinical-stage biotech and does not include any financial terms, guidance, or material operational changes.
Key Facts
- Dr. Suresh Durgam appointed to Board of Directors; previously served on Scientific Advisory Board
- Dr. Durgam was EVP and CMO of Intra-Cellular Therapies (acquired by J&J in April 2025) and led CAPLYTA FDA approvals
- Appointment subject to Cboe Canada approval
- No financial terms, equity grants, or compensation disclosed
- No changes to pipeline, guidance, or capital structure
Financial Impact
No financial impact disclosed — routine board appointment with no compensation terms or operational changes
Risk Factors
- Cboe Canada may not approve the appointment
- No change to pipeline execution risk for HLP003 (Phase 3) or HLP004 (Phase 2)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381528 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.19 (+0.79%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.19 (−6.13%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.19 (−2.95%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.19 (−7.78%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.19 (−7.78%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.19 (−4.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers